drugset / Trial / NCT06936644
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
Phase 2
Not yet recruiting
39 enrolled
Shanghai Chest Hospital
Akesobio · collabInnovent Biologics, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A multicenter, single-arm Phase II study to evaluate the efficacy and safety of fulzerasib (IBI351) in combination with ivonescimab (AK-112) in first-line treatment of advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation
Timeline
- Start
- 2025-04-30
- Primary completion
- 2027-04-30
- Completion
- 2028-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulzerasib | Small molecule | — | — |
| Subject | Ivonescimab | Monoclonal antibody | — | — |